Q-omics provides the consensus-scored MT-ND3 profile across patient tissues and cancer cell-line models. MT-ND3 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, MT-ND3 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, MT-ND3 RNA expression shows 18,471 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, KIRC, and UVM as cancer lineages where MT-ND3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MT-ND3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MT-ND3 survival associations across molecular data types. MT-ND3 RNA expression shows survival associations in the most cancer types (22), followed by mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MT-ND3 RNA expression–survival associations across cancer types. High MT-ND3 expression shows unfavorable associations in THYM and SKCM, but favorable associations in KIRP, LUSC, LGG and UVM. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify KIRP as the clearest survival context for MT-ND3 RNA expression.
This table summarizes MT-ND3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MT-ND3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MT-ND3 shows lower tumor expression in KIRC, KIRP, BRCA, LIHC, BLCA and COAD. The KIRC box plot shows higher MT-ND3 RNA expression in normal versus tumor tissue (log2 FC = −1.039, t-test p < 0.001).
This table shows molecular features associated with MT-ND3 in patient tissues and cancer cell lines. In patient samples, MT-ND3 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, MT-ND3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
